C4 Therapeutics Net Income vs. Shares Outstanding

CCCC Stock  USD 1.96  0.07  3.45%   
Based on C4 Therapeutics' profitability indicators, C4 Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess C4 Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2019-03-31
Previous Quarter
-26 M
Current Value
-32.2 M
Quarterly Volatility
9.2 M
 
Covid
 
Interest Hikes
As of January 30, 2026, Price To Sales Ratio is expected to decline to 7.67. In addition to that, Days Sales Outstanding is expected to decline to 34.76. At present, C4 Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 17.4 M, whereas Operating Income is forecasted to decline to (113 M). At present, C4 Therapeutics' Gross Profit Margin is projected to increase slightly based on the last few years of reporting.
For C4 Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of C4 Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well C4 Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between C4 Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of C4 Therapeutics over time as well as its relative position and ranking within its peers.
Check out Trending Equities.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.By analyzing C4 Therapeutics' earnings estimates, investors can diagnose different trends across C4 Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for C4 Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
C4 Therapeutics is projected to generate -0.38 in earnings per share on the 31st of December 2025. C4 Therapeutics earnings estimates show analyst consensus about projected C4 Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on C4 Therapeutics' historical volatility. Many public companies, such as C4 Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing C4 Therapeutics' earnings estimates, investors can diagnose different trends across C4 Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.67)
Revenue Per Share
0.423
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.23)
Return On Equity
(0.60)
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value—what C4 Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

C4 Therapeutics Shares Outstanding vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth.
C4 Therapeutics is rated below average in net income category among its peers. It is rated third in shares outstanding category among its peers . At present, C4 Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.

CCCC Shares Outstanding vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

C4 Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(105.32 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

C4 Therapeutics

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
96.91 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

CCCC Shares Outstanding Comparison

C4 Therapeutics is currently under evaluation in shares outstanding category among its peers.

C4 Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in C4 Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, C4 Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of C4 Therapeutics' change in net profit over the period of time. It can combine multiple indicators of C4 Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income61 K64 K
Net Interest Income16.6 M17.4 M
Interest Income16.6 M17.4 M
Operating Income-107.7 M-113 M
Net Loss-94.8 M-99.5 M
Income Before Tax-94.7 M-99.4 M
Total Other Income Expense Net16.6 M17.4 M
Net Loss-115.4 M-109.6 M
Net Loss-94.8 M-99.5 M
Income Tax Expense117.9 K112 K
Non Operating Income Net Other-2.3 M-2.4 M
Change To Netincome34.5 M36.2 M
Net Loss(1.75)(1.83)
Income Quality 0.56  0.43 
Net Income Per E B T 1.15  1.11 

CCCC Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on C4 Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of C4 Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the C4 Therapeutics' important profitability drivers and their relationship over time.

C4 Therapeutics Earnings per Share Projection vs Actual

Use C4 Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if C4 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in C4 Therapeutics will appreciate offsetting losses from the drop in the long position's value.

C4 Therapeutics Pair Trading

C4 Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to C4 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace C4 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back C4 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling C4 Therapeutics to buy it.
The correlation of C4 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as C4 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if C4 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for C4 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your C4 Therapeutics position

In addition to having C4 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USD Crypto Fund Thematic Idea Now

USD Crypto Fund
USD Crypto Fund Theme
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All  Next Launch
When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:
Check out Trending Equities.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project C4 Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of C4 Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include C4 Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential C4 Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although C4 Therapeutics investors may work on each financial statement separately, they are all related. The changes in C4 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on C4 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.